Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations-Reference-Cited by-全球学者库

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations

Published:2022-01 Issue:1 Volume:23 Page:e69-e82
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Hayashi Hidetoshi,Nadal Ernest,Gray Jhanelle E.,Ardizzoni Andrea,Caria Nicola,Puri Tarun,Grohe Christian

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference119 articles.

1. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

2. World Health Organization. Cancer - key facts. Accessed from: https://www.who.int/news-room/fact-sheets/detail/cancer. 2018. Accessed at: February 16, 2021.

3. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII);Midha;Am J Cancer Res,2015

4. Worldwide frequency of commonly detected EGFR mutations;Graham;Arch Pathol Lab Med,2018

5. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer;Noronha;J Clin Oncol,2020

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database;Int. Journal of Clinical Pharmacology and Therapeutics;2024-02-01

2. Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer;Thoracic Cancer;2024-01-26

3. Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib;Therapeutic Advances in Medical Oncology;2024-01

4. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-01

5. Long-term follow-up of a consecutive cohort validating an epidermal growth factor receptor mutation as an independent risk factor for postoperative recurrence in lung adenocarcinoma;Interdisciplinary CardioVascular and Thoracic Surgery;2023-10-31